| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.0M | — | -2.9% |
| R&D Expense | $2.9M | — | +63.2% |
| SG&A Expense | $5.3M | — | +86.1% |
| Operating Income | -$7.1M | — | -101.3% |
| Net Income | -$6.9M | — | +60.1% |
| EPS (Basic) | -$1.05 | — | +11.8% |
| EPS (Diluted) | -$1.05 | — | +11.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3.0M | -29.0% | -69.4% |
| Short-term Investments | $12.1M | +177.6% | — |
| Current Assets | $18.0M | +18.8% | +65.9% |
| Total Assets | $19.9M | +22.0% | +65.2% |
| Current Liabilities | $8.0M | -35.4% | -24.7% |
| Total Liabilities | $8.0M | -35.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$6.2M | — | -1.1% |
| Capital Expenditures | $818K | — | — |
| Investing Cash Flow | -$8.5M | — | -339.8% |
| Financing Cash Flow | $9.0M | — | -27.2% |
| Free Cash Flow | -$7.1M | — | -14.3% |
| -77.7% |
| Stockholders' Equity | $12.0M | +199.3% | +150.6% |